MarginsXMarginsX
Home › Markets › Health Care › CGC

Canopy Growth Corporation Common Shares (CGC)

CGC trades on Nasdaq in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.5460
-2.71% on the day
Market cap
$231.2M
Micro cap
Revenue · 2025
$199.6M
No prior year to compare
Net income · 2025
-$184.4M
-92.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-03-31, https://www.sec.gov/Archives/edgar/data/1737927/000119312526270260/0001193125-26-270260-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-03-31. Converted from CAD at 1.4258 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerCGC on Nasdaq
SectorHealth Care
Industry Medicinal Chemicals and Botanical Products
CountryCanada
IPO yearNot reported by the screener
SEC CIK0001737927
SEC industry codeMedicinal Chemicals & Botanical Products
Incorporated inCanada
Canadian listingTSX: WEED

Financials · 2025

LineValue
Revenue$199.6M
Net income-$184.4M
Operating income-$113.4M
Net margin-92.4%
Operating margin-56.8%
Revenue growthNo prior-year revenue to compare
Cash$255.8M
Total assets$784.6M
P/E (computed)Net income was not positive
P/S (computed)1.2×

Reported in CAD; shown in US dollars.

Warning signs

Cash runway
68.6 months
$255.8M cash at March 31, 2026
Share count, 1 year
+23.7%
2025-10-31 to 2026-11-04
Going-concern doubt
No
10-Q filed November 6, 2026
Insider net buying, 12 months
-$388K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-06
Cash and burn$255.8M cash; operating cash flow -$11.2M a quarter.Report 2026-03-31
Shares outstanding423,352,668 (2026-11-04); 342,195,956 a year earlier.Cover page 2026-11-04
Reverse splits, 3 years1; latest 1-for-10 on 2023-12-20Source 2023-12-20
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-02-06
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-10-16
AuditorPKF O'Connor Davies, LLP, New York, New York, United States; changed auditors 1 time in 24 months8-K 4.01 2026-08-07
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $388K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2026
2026-03-31
$199.6M-$184.4M-$44.8M$255.8M$163.7M$199.6M10-K 2026-06-15

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-02-13
Latest annual report10-K2026-06-15
Latest quarterly / interim10-Q2026-11-06
Latest current report8-K2026-11-06
Latest proxyDEFA14A2026-10-16

Source: SEC EDGAR submissions feed, 765 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-14.0%
1 month-26.5%
3 months-44.5%
Year to date-50.8%
1 year-49.0%
From 52-week high-70.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Medicinal Chemicals and Botanical Products

TickerCompanyPriceDayMarket cap
USNAUSANA Health Sciences Inc.$13.54+2.27%$250.3M
MDWDMediWound Ltd.$13.55+5.04%$195.0M
ACBAurora Cannabis Inc. Common Shares$4.61-6.68%$303.1M
SNDLSNDL Inc. Common Shares$1.34-2.19%$326.0M
NAGENiagen Bioscience Inc.$2.01-2.66%$159.2M
TLRYTilray Brands Inc. Common Stock$2.34-3.70%$345.8M
GLASGlass House Brands Inc. Subordinate Voting Shares$1.29+1.57%$113.5M
OBIOOrchestra BioMed Holdings Inc.$7.12-1.79%$560.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier